MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This development overshadowed the company's second-quarter earnings report released earlier in the day.

The strategic financing agreement, valued at up to $500 million, includes an initial term loan of $75 million to be funded at closing. The facility also provides for a $125 million delayed draw term loan available for up to 24 months, and an additional $300 million uncommitted delayed draw term loan subject to mutual consent. Set to mature in August 2030, the facility bears interest at the secured overnight financing rate plus 4.75%.

This substantial financing deal is expected to significantly bolster MannKind's financial position, potentially accelerating the company's growth initiatives and pipeline development. The biopharmaceutical firm, known for its inhaled insulin product Afrezza and other pulmonary therapeutics, could use these funds to expand its product portfolio, enhance its manufacturing capabilities, or pursue strategic acquisitions. While the company's Q2 revenue grew by 6% to $76.5 million, slightly missing analyst estimates, investors seem more focused on the long-term potential unlocked by this new financing arrangement with Blackstone.